We have located links that may give you full text access.
N-terminal-pro-B-type natriuretic peptide (NT-proBNP): reference range for Chinese apparently healthy people and clinical performance in Chinese elderly patients with heart failure.
BACKGROUND: N-terminal-pro-B-type natriuretic peptide (NT-proBNP) has been found to be a useful marker for the diagnosis of heart failure (HF) and left ventricular systolic dysfunction. We established a reference range for Chinese apparently healthy people based on age and gender and evaluated the clinical performance of NT-proBNP in the diagnosis of asymptomatic and symptomatic HF.
METHODS: A group of 442 apparently healthy subjects were enrolled for reference range study. For the clinical performance study, serum NT-proBNP and clinical data were analyzed in 111 elderly patients with HF and 60 normal elderly controls. Serum NT-proBNP was measured by the Roche Elecsys 2010 immunoassay analyzer.
RESULTS: NT-proBNP reference range in Chinese people based on age and gender was <83.72 ng/l for men and <131.6 ng/l for women aged 60 years, which were lower than those for western countries. NT-proBNP had a close correlation with New York Heart Association (NYHA) classification (r=0.818) and LVEF (r=-0.636). The ROC curve analysis revealed an AUC of 0.921 for the diagnosis of HF, 0.840 for asymptomatic HF (NYHA I) and 0.951 for symptomatic HF (NYHA II-IV). The optimal cutoff values for detecting HF, asymptomatic HF and symptomatic HF were 102.2, 102.2, and 204.8 ng/l, respectively. NT-proBNP had high positive predictive value (PPV) for the diagnosis of HF (96.8%), asymptomatic HF (90.3%) and symptomatic HF (90.9%), but low negative predictive value (NPV) for diagnosing HF and asymptomatic HF (74.0% and 78.1%, respectively) except symptomatic HF (93.3%).
CONCLUSIONS: Chinese people have lower reference range of serum NT-proBNP. NT-proBNP assay has a good clinical performance for the diagnosis of symptomatic HF but is not suitable as a screening test for HF.
METHODS: A group of 442 apparently healthy subjects were enrolled for reference range study. For the clinical performance study, serum NT-proBNP and clinical data were analyzed in 111 elderly patients with HF and 60 normal elderly controls. Serum NT-proBNP was measured by the Roche Elecsys 2010 immunoassay analyzer.
RESULTS: NT-proBNP reference range in Chinese people based on age and gender was <83.72 ng/l for men and <131.6 ng/l for women aged 60 years, which were lower than those for western countries. NT-proBNP had a close correlation with New York Heart Association (NYHA) classification (r=0.818) and LVEF (r=-0.636). The ROC curve analysis revealed an AUC of 0.921 for the diagnosis of HF, 0.840 for asymptomatic HF (NYHA I) and 0.951 for symptomatic HF (NYHA II-IV). The optimal cutoff values for detecting HF, asymptomatic HF and symptomatic HF were 102.2, 102.2, and 204.8 ng/l, respectively. NT-proBNP had high positive predictive value (PPV) for the diagnosis of HF (96.8%), asymptomatic HF (90.3%) and symptomatic HF (90.9%), but low negative predictive value (NPV) for diagnosing HF and asymptomatic HF (74.0% and 78.1%, respectively) except symptomatic HF (93.3%).
CONCLUSIONS: Chinese people have lower reference range of serum NT-proBNP. NT-proBNP assay has a good clinical performance for the diagnosis of symptomatic HF but is not suitable as a screening test for HF.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app